



ASX ANNOUNCEMENT

Change in Reporting Currency

MELBOURNE, Australia (31 January 2022): Lumos Diagnostics (ASX: LDX) advises that, in accordance with AASB 108 'Accounting Policies' it has voluntarily changed its presentation currency from Australian dollars to US dollars.

Given that the Company's revenue and most of its costs are denominated in US dollars, the Board believes that the change will give investors and other stakeholders a clearer understanding of Lumos' performance over time.

The change means that financial information in the Company's quarterly reports commencing from the quarter ended 31 December 2021, as well as its annual and interim financial reports, will be presented in US dollars.

For comparative purposes, restated historical information will be included in the Half Year report for the six months ended 31 December 2021 and the Annual Report for the year ended 30 June 2022.

Commenting on the change, Lumos' CEO and Managing Director, Dr Robert Sambursky, said:

"The change in reporting currency is another step forward in Lumos' operations as a fully integrated developer and manufacturer of point-of-care diagnostic tests. The change better reflects the underlying transactions of the Company, reporting in US dollars will simplify comparisons with Lumos' peer group, most of which report in US dollars."

This announcement was authorised by the Disclosure Committee.

-Ends-

About Lumos Diagnostics

Lumos Diagnostics specialises in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customised assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercialises novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information about Lumos Diagnostics and the CoviDx SARS-CoV-2 rapid antigen test, visit lumosdiagnostics.com.

Media Contacts (U.S. and Global):

Jennifer Christiansen – Lumos Diagnostics
jennifer.christiansen@lumosdiagnostics.com
+1 920 784 3153



Investor Contact:

Matthijs Smith
ir@lumosdiagnostics.com
+61 411 137 080
+61 3 9087 1598

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205
+61 3 9087 1598